Esperion Therapeutics’ (ESPR) “Market Outperform” Rating Reiterated at JMP Securities
JMP Securities reissued their market outperform rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They ...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Detailed price information for Esperion Theraptc (ESPR-Q) from The Globe and Mail including charting and trades.
Esperion stock holds Buy rating, $16 target from H.C. Wainwright
H.C. Wainwright maintained a positive stance on Esperion Therapeutics (NASDAQ:ESPR) shares, reaffirming a Buy rating and a price target of $16.00. According to InvestingPro data, analyst targets for ...
Esperion stock target cut to $4 by JMP Securities
JMP Securities adjusted its price target for Esperion Therapeutics (NASDAQ:ESPR) shares, lowering it to $4.00 from the previous $7.00. Currently trading at $1.86, the stock sits well below analyst ...
Esperion price target lowered to $4 from $7 at JMP Securities
JMP Securities lowered the firm’s price target on Esperion (ESPR) to $4 from $7 and keeps an Outperform rating on the shares. JMP updated its ...
Esperion (ESPR) Receives a Sell from Bank of America Securities
In a report released today, Jason Zemansky from Bank of America Securities maintained a Sell rating on Esperion (ESPR – Research Report), with ...
Yahoo Finance24d
Esperion Therapeutics, Inc. (ESPR)
Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) ...
Pharmaceutical Technology26d
Bempedoic acid by Esperion Therapeutics for Hypercholesterolemia: Likelihood of Approval
Bempedoic acid is under clinical development by Esperion Therapeutics and currently in Phase II for Hypercholesterolemia. According to GlobalData, Phase II drugs for Hypercholesterolemia have a 57% ...